David Dworaczyk, PhD, Presents Phase 3 Data on Novel Intranasal Epinephrine


Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

For more than 4 decades, self-injected epinephrine has been used as immediate treatment for anaphylaxis. Today, a novel intranasal (IN) epinephrine spray Utuly was introduced during a presentation on breakthrough phase 3 data at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting in San Antonio, TX.

"Results from the study clearly showed that we had a product that delivers a pharmacokinetics profile that is higher and more prolonged compared to the EpiPen, with an equal or better rate of absorption so that the plasma concentrations reach threshold levels of 100.2 grams per milliliter, as rapidly as they do with an EpiPen," David David Dworaczyk, PhD, CEO, Bryn Pharma, said in an interview with HCPLive.

The study aimed to compare the pharmacokinetics (PK) of the novel intranasal epinephrine spray with an epinephrine autoinjector and prefilled manual syringe, which is the current standard for treatment. Utuly demonstrated an enhanced pharmacokinetics profile compared with the 0.3mg epinephrine autoinjector.

"(The plasma concentrations of Utuly) go up higher, and they stay high longer than an EpiPen–essentially twice as long as an EpiPen," he continued. "So, you have essentially twice as long between the initial event treatment and to seeking emergency medical attention."

Additionally, safety results for the route of administration for Utuly and intramuscular (IM) administration were comparable, indicating that Utuly was well-tolerated with no new safety signals for the intranasal route of administration. There were no significant adverse events reported in the study.

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.